An Open Label Study in Healthy Volunteers to Evaluate the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs F 901318 (Primary) ; Midazolam
- Indications Aspergillosis
- Focus Pharmacokinetics
- Sponsors F2G
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
- 08 Jun 2016 Status changed from recruiting to completed.
- 18 Feb 2016 New trial record